AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04090515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: This intervention involves a one-hour group meeting for six consecutive weeks.
Study NCT06385379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system
Description: The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
Study NCT04090515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Video Control
Description: This intervention involves a one-hour educational video control viewing for six consecutive weeks.
Study NCT00944593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jejunal Feed
Description: Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
Study NCT00944593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 200ml Normal Saline 0.9%
Study NCT05254912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol in sunscreen formulation
Description: 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
Study NCT05254912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Bemotrizinol in petrolatum
Description: 6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
Study NCT05254912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
Study NCT04820049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F573
Description: F573 for injection
Study NCT04820049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water for injection
Study NCT04942184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory strategies in Arm 1
Description: Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
Study NCT04942184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG) headset in Arm 1
Description: A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
Study NCT04942184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet in Arm 1
Description: A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
Study NCT04942184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory strategies in Arm 2
Description: Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
Study NCT06246864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Description: After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
Study NCT06246864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoallergenic Flexible
Description: After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
Study NCT05657249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-contrast focused MRI
Description: non-contrast liver MRI focusing on HCC surveillance in a short scan time.
Study NCT04823286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality health platform during hemodialysis
Description: Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
Study NCT06485713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil combined with fufuquitinib
Description: trifluridine/tipiracil combined with fufuquitinib
Study NCT06485713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fufuquitinib
Description: fufuquitinib
Study NCT06485713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil
Study NCT05542095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
Study NCT04659304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allocetra-OTS
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Study NCT04942184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram (EEG) headset in Arm 2
Description: A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
Study NCT04942184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tablet in Arm 2
Description: A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
Study NCT05247437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intensive Lifestyle Intervention
Description: The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
Study NCT05247437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Self-Help Control Condition
Description: The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
Study NCT06510166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's Fear and Anxiety normal nebulizer and mask+ distraction
Description: Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
Study NCT06510166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Children's Fear and Anxiety a toy nebulizer and a toy mask
Description: Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
Study NCT05267769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP707
Description: Preparation of Cannabis flowers (Cannabis flos)
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Description: Single pill
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Description: Signle pill
Study NCT05335928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept plus
Description: Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Study NCT05335928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Study NCT05873686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXP900
Description: NXP900 is an orally administered SRC/YES1 kinase inhibitor
Study NCT05403905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non surgical treatment
Description: Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
Study NCT04839068 — intervention group
Intervention type: DEVICE
Intervention: covid 19 on pregnancy outcomes
Description: covid 19 on pregnancy outcomes and sex ratio at birth
Study NCT05403905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment
Description: The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 20 mg/amlodipine 2.5 mg .
Description: oral tablet
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan 40 mg/amlodipine 5 mg
Description: oral tablet
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 20 mg/indapamide 1.25 mg
Description: oral tablet
Study NCT05322291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobil Application
Description: The mobile application developed will be installed on the phones of hemodialysis patients
Study NCT05555641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
Study NCT05555641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
Study NCT05414448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOCUFF
Description: ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
Study NCT06549166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: VR and exercise
Description: Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
Study NCT06549166 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: exercise
Description: The control group will perform a 40-minute same neck exercises.
Study NCT04731298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first.
Study NCT05090163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREP Plus
Description: Group based exercise in addition to PREP exercises
Study NCT05090163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREP
Description: Group based exercise
Study NCT04409561 — intervention group
Intervention type: DEVICE
Intervention: Blood collection
Description: 9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan 40 mg/indapamide 2.5 mg
Description: oral tablet
Study NCT05808595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaWave® L-Theanine
Description: One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
Study NCT05808595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of Placebo will be taken twice daily for 28 days.
Study NCT04558723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implantation
Description: ICD/CRT-D implantation (if indicated)
Study NCT06008236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation and Breathing Exercises
Description: Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
Study NCT05403476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Description: FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5 mg/indapamide 1.25 mg
Description: oral tablet
Study NCT05403476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
Study NCT04518293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5 mg/indapamide 2.5 mg
Description: oral tablet
Study NCT06489626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 4 milligram Tab
Description: 6-day 4 milligram methylprednisolone oral taper
Study NCT06489626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: 4 milligram intravenous dexamethasone will be administered intraoperatively
Study NCT06489626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: 4 milligram intravenous dexamethasone will be administered intraoperatively
Study NCT06632249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice with the virtual reality game
Description: 4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
Study NCT06632249 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Practice with the virtual reality game
Description: 4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
Study NCT06634121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter mitral valve edge-to-edge repair (M-TEER)
Description: M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
Study NCT05565599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure
Description: Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
Study NCT05906914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine + homoharringtonine + cytarabine
Description: CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
Study NCT06634186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
Study NCT04887155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Group-based transdiagnostic cognitive-behavioral treatment
Study NCT04887155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Group-based transdiagnostic cognitive-behavioral treatment
Study NCT05434637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
Study NCT05434637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound-based Therapy
Description: Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
Study NCT05434637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
Study NCT05307510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefabricated splint
Description: Subjects will be provided either a prefabricated splint
Study NCT05307510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Orthosis
Description: Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
Study NCT06633341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR T-cells
Description: Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
Study NCT06273267 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
Study NCT05742763 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and PRP
Description: The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.